Open AccessComparison of pre‑implant treatment planning and post‑implant dosimetry in I‑125 spinal metastases brachytherapy
Author(s) -
Guohua Chen,
Mingyong Han
Publication year - 2019
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2019.11106
Subject(s) - brachytherapy , dosimetry , implant , medicine , nuclear medicine , radiation treatment planning , radiation therapy , radiology , surgery
I-125 seed therapy has been developed and used for the treatment of numerous types of malignancies. It has been suggested that post-implant dosimetry deviates from pre-implant treatment planning; however, to the best of our knowledge, very few studies to date have investigated this discrepancy. In the present study, 11 patients with metastatic spinal tumors, who were treated with I-125 seed brachytherapy, were assessed. Pre- and post-implant dosimetry were compared by assessing: Tumor volume, dose distributions and dose volume histograms. The average doses delivered to 90% of the target volume (D90) in the pre-implant planning images of the spine was 119.07 Gy compared with 94.15 Gy in the post-implant dosimetry (P<0.05). The average V100 in the pre-implant planning images of the spine was 97.85% (range, 96.50-99.80%), compared with 84.46% (range, 66.40-96.70%) in the post-implant dosimetry, of the prescribed doses (P<0.05). Furthermore, both the number of needles and the Dmax of the cord differed between the two groups. Nevertheless, the mean gross tumor volume, the number of seeds, and the V150 and V200 were similar between the two groups. The results of the present study suggest that metastatic spinal tumors of the bone received a lower dose than the pre-implant planned dose coverage in I-125 seed brachytherapy.